Search

Displaying results 2111 - 2120 of 3020 in total
  1. Drug

    Maraviroc

    go.drugbank.com/drugs/DB04835
    ApprovedInvestigational

    It was approved for use by the FDA in August, 2007.

  2. Drug

    Elapegademase

    go.drugbank.com/drugs/DB14712
    Approved

    [F1937] Elapegademase is generated in _E. coli_, developed by Leadiant Biosciences and FDA approved on October 5, 2018.[L4654,F1939]

    Synonyms: (74-SERINE (C>S),245-THREONINE (A>T))BOS TAURUS ADENOSINE DEAMINASE (BOVINE ADENOSINE AMINOHYDROLASE, EC=3.5.4.4)-(1-356)-PEPTIDE PRODUCED IN ESCHERICHIA COLI, AN AVERAGE OF 13 RESIDUES ARE SUBSTITUTED
  3. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603]

  4. Drug

    Norgestimate

    go.drugbank.com/drugs/DB00957
    ApprovedInvestigational

    [L11845,L11848] Norgestimate was granted FDA approval on 29 December 1989.[L11842]

    Synonyms: d-13β-Ethyl-17α-ethynyl-17β-acetoxygon-4-en-3-one oxime, (17α)-17-(Acetyloxy)-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one 3-oxime
  5. Drug

    Pindolol

    go.drugbank.com/drugs/DB00960
    ApprovedInvestigational

    [A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348]

    Products: Nu-pindol Tab 5mg, Nu-pindol Tab 10mg
  6. Drug

    Ranirestat

    go.drugbank.com/drugs/DB05327
    Investigational

    Ranirestat is a structurally novel and stereospecifically potent aldose reductase (AKR1B; EC 1.1.1.21) inhibitor, which contains a succinimide ring that undergoes ring-opening at physiological pH levels

  7. Drug

    BB 21217

    go.drugbank.com/drugs/DB17373
    Investigational

    BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP

  8. Drug

    Zinc protoporphyrin

    go.drugbank.com/drugs/DB03934
    Experimental

    Categories: Heme Oxygenase (Decyclizing), antagonists & inhibitors
  9. Drug

    Eliapixant

    go.drugbank.com/drugs/DB21465
    Investigational

    Eliapixant is under investigation in clinical trial NCT04614246 (Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive

  10. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).